Capital Fund Management (CFM)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$686K Sell
58,644
-6,750
-10% -$110K ﹤0.01% 1645
2026
Q2
$1.27M Buy
65,394
+54,134
+481% +$981K 0.01% 1614
2026
Q1
$210K Buy
+11,260
New +$187K ﹤0.01% 2000
2024
Q3
– Sell
-29,243
Closed -$1.29M – 2086
2024
Q2
$1.29M Buy
+29,243
New +$1.24M ﹤0.01% 1536

Other funds holding MLTX

Capital Fund Management (CFM)'s MLTX Position: Q3 2026 in Review

Capital Fund Management (CFM) reduced its MoonLake Immunotherapeutics (MLTX) stake by 10% in Q3 2026, selling an estimated $110K and leaving 58,644 shares worth $686K. The position accounts for ﹤0.01% of the portfolio, ranked #1645.

Capital Fund Management (CFM) first reported a position in MLTX in Q2 2024 and has held it in 4 quarters since. The position peaked at $1.29M in Q2 2024. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Capital Fund Management (CFM) held 58,644 shares of MoonLake Immunotherapeutics worth $686K as of Q3 2026.
  • Capital Fund Management (CFM) sold 6,750 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $110K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q3 2026, its #1645 holding.
  • Capital Fund Management (CFM) first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 4 quarters since.
  • Capital Fund Management (CFM)'s MoonLake Immunotherapeutics position peaked at $1.29M in Q2 2024.
  • 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2026, filed 13 Nov 2026.